Paul C Adamson1, Eric Y Lin2, Sung-Min Ha3, Jeffrey D Klausner4. 1. Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. 2. David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. 3. Department of Integrative Biology and Physiology, University of California, Los Angeles, CA, USA. 4. Department of Preventive Medicine, Keck School of Medicine of USC, Los Angeles, CA, USA.
Abstract
BACKGROUND: Antimicrobial resistance (AMR) in Neisseria gonorrhoeae is an urgent global health threat. Zoliflodacin is a novel antibiotic undergoing clinical trials for the treatment of gonorrhoea. While there are limited data regarding zoliflodacin resistance in N. gonorrhoeae, three amino acid mutations have been associated with increased MICs of zoliflodacin. OBJECTIVES: To determine the prevalence of three amino acid mutations associated with zoliflodacin resistance within a large, public database of nearly 13 000 N. gonorrhoeae genomes. METHODS: PathogenWatch is an online genomic epidemiology platform with a public database of N. gonorrhoeae genomes. That database was used to extract gyrB sequence data and a Basic Local Alignment Search Tool (BLAST) search was performed to identify any of the three amino acid mutations in GyrB that are associated with increased zoliflodacin MICs: D429N, K450N or K450T. As a control for the search methodology, all GyrA sequences were also extracted and S91F mutations were identified and compared with the PathogenWatch database. RESULTS: In total, 12 493 N. gonorrhoeae genomes from the PathogenWatch database were included. Among those genomes, none was identified that harboured any of the three mutations associated with increased zoliflodacin MICs. One genome was identified to have a mutation at position 429 in GyrB (D429V). CONCLUSIONS: The findings suggest that the prevalence of the three mutations associated with zoliflodacin resistance in N. gonorrhoeae is very low. However, further research into the mechanisms of zoliflodacin resistance in N. gonorrhoeae is needed. Genomic epidemiology platforms like PathogenWatch can be used to enhance the global surveillance of AMR.
BACKGROUND: Antimicrobial resistance (AMR) in Neisseria gonorrhoeae is an urgent global health threat. Zoliflodacin is a novel antibiotic undergoing clinical trials for the treatment of gonorrhoea. While there are limited data regarding zoliflodacin resistance in N. gonorrhoeae, three amino acid mutations have been associated with increased MICs of zoliflodacin. OBJECTIVES: To determine the prevalence of three amino acid mutations associated with zoliflodacin resistance within a large, public database of nearly 13 000 N. gonorrhoeae genomes. METHODS: PathogenWatch is an online genomic epidemiology platform with a public database of N. gonorrhoeae genomes. That database was used to extract gyrB sequence data and a Basic Local Alignment Search Tool (BLAST) search was performed to identify any of the three amino acid mutations in GyrB that are associated with increased zoliflodacin MICs: D429N, K450N or K450T. As a control for the search methodology, all GyrA sequences were also extracted and S91F mutations were identified and compared with the PathogenWatch database. RESULTS: In total, 12 493 N. gonorrhoeae genomes from the PathogenWatch database were included. Among those genomes, none was identified that harboured any of the three mutations associated with increased zoliflodacin MICs. One genome was identified to have a mutation at position 429 in GyrB (D429V). CONCLUSIONS: The findings suggest that the prevalence of the three mutations associated with zoliflodacin resistance in N. gonorrhoeae is very low. However, further research into the mechanisms of zoliflodacin resistance in N. gonorrhoeae is needed. Genomic epidemiology platforms like PathogenWatch can be used to enhance the global surveillance of AMR.
Authors: Sunniva Foerster; George Drusano; Daniel Golparian; Michael Neely; Laura J V Piddock; Emilie Alirol; Magnus Unemo Journal: J Antimicrob Chemother Date: 2019-12-01 Impact factor: 5.790
Authors: Christiam Camacho; George Coulouris; Vahram Avagyan; Ning Ma; Jason Papadopoulos; Kevin Bealer; Thomas L Madden Journal: BMC Bioinformatics Date: 2009-12-15 Impact factor: 3.169
Authors: Peter J A Cock; Tiago Antao; Jeffrey T Chang; Brad A Chapman; Cymon J Cox; Andrew Dalke; Iddo Friedberg; Thomas Hamelryck; Frank Kauff; Bartek Wilczynski; Michiel J L de Hoon Journal: Bioinformatics Date: 2009-03-20 Impact factor: 6.937
Authors: Daniel Golparian; Simon R Harris; Leonor Sánchez-Busó; Steen Hoffmann; William M Shafer; Stephen D Bentley; Jörgen S Jensen; Magnus Unemo Journal: BMC Genomics Date: 2020-02-03 Impact factor: 3.969
Authors: David W Eyre; Nicholas D Sanderson; Emily Lord; Natasha Regisford-Reimmer; Kevin Chau; Leanne Barker; Markus Morgan; Robert Newnham; Daniel Golparian; Magnus Unemo; Derrick W Crook; Tim Ea Peto; Gwenda Hughes; Michelle J Cole; Helen Fifer; Anne Edwards; Monique I Andersson Journal: Euro Surveill Date: 2018-07
Authors: Jane Rowley; Stephen Vander Hoorn; Eline Korenromp; Nicola Low; Magnus Unemo; Laith J Abu-Raddad; R Matthew Chico; Alex Smolak; Lori Newman; Sami Gottlieb; Soe Soe Thwin; Nathalie Broutet; Melanie M Taylor Journal: Bull World Health Organ Date: 2019-06-06 Impact factor: 9.408
Authors: Susanne Jacobsson; Daniel Golparian; Joakim Oxelbark; Francois Franceschi; David Brown; Arnold Louie; George Drusano; Magnus Unemo Journal: Front Pharmacol Date: 2022-04-14 Impact factor: 5.988